Victor O. Etikudike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Victor O. Etikudike has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Angus Nnamdi Oli
Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria
1 shared publication - Charles Okeke Nnadi
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Nigeria
1 shared publication - Chinyere Constance Ezemba
Chukwuemeka Odumegwu Ojukwu University; Chychy Gilgal Limited
1 shared publication - Chioma C. Ezeuko
Microbiology Program, College of Science, Technology, Engineering and Mathematics Alabama State University Montgomery Alabama 36104 USA alasu.edu
1 shared publication - Chioma Miracle Ojiako
School of Science, Technology and Engineering University of the Sunshine Coast 90 Sippy Downs Drive Sippy Downs Queensland 4556 Australia usc.edu.au
1 shared publication - Kasso Terhemen
Department of Obstetrics and Gynaecology University of Port-Harcourt Port-Harcourt Nigeria unicamp.br
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1) , 5663176
Mechanisms, Significance, Detection and Emerging Therapies for Carbapenem‐Resistant Enterobacterales: A Scoping Review
Background: Carbapenems are among the most important broad‐spectrum β‐lactam antibiotics for the treatment of severe infections caused by multi–drug‐resistant Gram‐negative bacteria. However, the global emergence and dissemination of carbapenem‐resistant Enterobacterales (CRE), particularly carbapenemase‐producing Enterobacterales (CPE), have significantly compromised their clinical utility. Resistance is primarily driven by the acquisition of genes encoding carbapenemases, often in combination with porin alterations, efflux pump overexpression and AmpC hyperproduction, resulting in limited treatment options and increased morbidity and mortality. Objectives: This scoping review aimed to synthesise current evidence on the molecular mechanisms of carbapenem resistance, the classification and epidemiology of carbapenemases, advances in diagnostic approaches and emerging therapeutic strategies for CRE infections. Methods: A scoping review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA‐ScR). Literature published between January 2005 and March 2026 was identified through systematic searches of PubMed/MEDLINE, Scopus and Google Scholar. Eligible studies included original research articles, surveillance reports, systematic reviews and clinical guidelines addressing carbapenem resistance mechanisms, carbapenemase epidemiology, diagnostics or treatment strategies. Data were extracted and synthesised using a narrative and thematic approach. Results: Carbapenemase production was identified as the predominant mechanism of resistance among CRE, with KPC, NDM, OXA‐48‐like, VIM and IMP enzymes driving global dissemination. Considerable geographical variation exists in carbapenemase distribution, reflecting differences in antimicrobial use, surveillance capacity and healthcare infrastructure. Advances in molecular diagnostics, including polymerase chain reaction, loop‐mediated isothermal amplification, whole‐genome sequencing and rapid immunochromatographic assays, have improved detection and surveillance. Emerging therapeutic options, particularly novel β‐lactam/β‐lactamase inhibitor combinations and cefiderocol, have expanded treatment possibilities, although resistance to newer agents continues to emerge. Conclusions: CREs remain a major global public health threat. Strengthened surveillance systems, improved access to rapid diagnostics, carbapenemase‐directed therapeutic strategies and continued antimicrobial development are essential to limit the spread of resistance and improve clinical outcomes.
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1) , 5663176
Open AccessMechanisms, Significance, Detection and Emerging Therapies for Carbapenem‐Resistant Enterobacterales: A Scoping Review
Background: Carbapenems are among the most important broad‐spectrum β‐lactam antibiotics for the treatment of severe infections caused by multi–drug‐resistant Gram‐negative bacteria. However, the global emergence and dissemination of carbapenem‐resistant Enterobacterales (CRE), particularly carbapenemase‐producing Enterobacterales (CPE), have significantly compromised their clinical utility. Resistance is primarily driven by the acquisition of genes encoding carbapenemases, often in combination with porin alterations, efflux pump overexpression and AmpC hyperproduction, resulting in limited treatment options and increased morbidity and mortality. Objectives: This scoping review aimed to synthesise current evidence on the molecular mechanisms of carbapenem resistance, the classification and epidemiology of carbapenemases, advances in diagnostic approaches and emerging therapeutic strategies for CRE infections. Methods: A scoping review was conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA‐ScR). Literature published between January 2005 and March 2026 was identified through systematic searches of PubMed/MEDLINE, Scopus and Google Scholar. Eligible studies included original research articles, surveillance reports, systematic reviews and clinical guidelines addressing carbapenem resistance mechanisms, carbapenemase epidemiology, diagnostics or treatment strategies. Data were extracted and synthesised using a narrative and thematic approach. Results: Carbapenemase production was identified as the predominant mechanism of resistance among CRE, with KPC, NDM, OXA‐48‐like, VIM and IMP enzymes driving global dissemination. Considerable geographical variation exists in carbapenemase distribution, reflecting differences in antimicrobial use, surveillance capacity and healthcare infrastructure. Advances in molecular diagnostics, including polymerase chain reaction, loop‐mediated isothermal amplification, whole‐genome sequencing and rapid immunochromatographic assays, have improved detection and surveillance. Emerging therapeutic options, particularly novel β‐lactam/β‐lactamase inhibitor combinations and cefiderocol, have expanded treatment possibilities, although resistance to newer agents continues to emerge. Conclusions: CREs remain a major global public health threat. Strengthened surveillance systems, improved access to rapid diagnostics, carbapenemase‐directed therapeutic strategies and continued antimicrobial development are essential to limit the spread of resistance and improve clinical outcomes.